News Releases

26 May '21
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 26, 2021-- Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease with topline data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative diseases, announced that Chris
26 Jan '21
— Based upon successful completion of the GAIN Trial’s interim analysis, pipeline expansion announced for 2021 — Atuzaginstat to be studied in the PEAK trial, a new Phase 2 study for Parkinson’s disease — COR588, a novel lysine gingipain inhibitor, on track to enter the clinic in Q3 2021 — Top-line